[1] Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol,2020,17:93-110. [2] Shah RA, Kowdley KV. Current and potential treatments for primary biliary cholangitis. Lancet Gastroenterol Hepatol,2020,5:306-315. [3] Liwinski T, Zenouzi R, John C, et al. Alterations of the bile microbiome in primary sclerosing cholangitis. Gut,2020,69:665-672. [4] Han FF, Fang MX, Zhao DT, et al. Profiling of the pattern of the human TRB/IGH-CDR3 repertoire in primary biliary cholangitis patients. Int Immunopharmacol,2020,83:106-107. [5] Funabashi M, Grove TL, Wang M, et al. A metabolic pathway for bile acid dehydroxylation by the gut microbiome. Nature,2020,582:566-570. [6] Corpechot C, Chazouilleres O, Belnou P, et al. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. J Hepatol,2020,73:559-565. [7] Leung KK, Deeb M, Hirschfield GM. Review article: pathophysiology and management of primary biliary cholangitis. Aliment Pharmacol Ther,2020,52:1150-1164. [8] Lindor KD, Bowlus CL, Boyer J, et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology,2019,69:394-419. [9] Galoosian A, Hanlon C, Zhang J, et al. Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches. J Clin Transl Hepatol,2020,8:49-60. [10] Younossi ZM, Bernstein D, Shiffman ML, et al. Diagnosis and Management of Primary Biliary Cholangitis. Am J Gastroenterol,2019,114:48-63. [11] Corpechot C, Poupon R, Chazouilleres O. New treatments/targets for primary biliary cholangitis. JHEP Rep,2019,1:203-213. [12] Vieira-Silva S, Sabino J, Valles-Colomer M, et al. Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC/IBD diagnoses. Nat Microbiol,2019,4:1826-1831. [13] Jang JS, Juran BD, Cunningham KY, et al. Single-cell mass cytometry on peripheral blood identifies immune cell subsets associated with primary biliary cholangitis. Sci Rep,2020,10:125-126. [14] Furukawa M, Moriya K, Nakayama J, et al. Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. Hepatol Res,2020,50:840-852. [15] Hegade VS, Pechlivanis A, Mcdonald J, et al. Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus. Liver Int,2019,39:967-975. [16] Liwinski T, Casar C, Ruehlemann MC, et al. A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis. Aliment Pharmacol Ther,2020,51:1417-1428. [17] 周思敏,刘曼,周璐,等. 自身免疫性肝病患者肝组织中菌群丰度和多样性的初步研究. 中华消化杂志,2019,39:244-250. [18] Manne V, Kowdley KV. Obeticholic acid in primary biliary cholangitis: where we stand. Curr Opin Gastroenterol,2019,35:191-196. [19] 郑玥琪,陈建杰,陆云飞,等. 原发性胆汁性胆管炎患者中医证候特征与熊去氧胆酸应答不佳的相关性研究. 中西医结合肝病杂志,2019,29:402-405. [20] Cargill T, Makuch M, Sadler R, et al. Activated T-Follicular Helper 2 Cells Are Associated With Disease Activity in IgG4-Related Sclerosing Cholangitis and Pancreatitis. Clin Transl Gastroenterol,2019,10:e00020. |